Marizyme
Jupiter
About Marizyme
Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $5.6M
- Last round: Series Unknown (Aug 2020)
- Website: marizyme.com
- Phone: (561)-935-9955
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/marizyme-55081 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.